Telix Pharmaceuticals Limited

TLX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$10.02+1.31%

2026-08-03

Financials

Valuation Metrics

Telix Pharmaceuticals Limited's Market Cap is $3.39B. Ranked #1683 of 3,112 in US market (top 54%), #599 of 1,445 on NASDAQ (top 41%), #99 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$3.39B	US#1,683/3,112 Sec#99/269
Revenue	$778M	US#2,088/3,112 Sec#63/269
Net Income	$-7M	US—/3,112 Sec—/269
Total Assets	$1.18B	US#2,374/3,112 Sec#88/269
Net Assets	$415M	US#2,389/3,112 Sec#129/269
Value
P/B	8.17x	US#2,505/3,112 Sec#191/269
P/S	4.36x	US#2,160/3,112 Sec#69/269
EV/EBITDA	73.28x	US#2,408/3,112 Sec#83/269
FCF Yield	-1.57%	US—/3,112 Sec—/269
Profitability
ROE	-1.66%	US#2,217/3,112 Sec#78/269
ROA	-0.58%	US#2,267/3,112 Sec#76/269
Op. Margin	2.21%	US#2,297/3,112 Sec#81/269
Revenue Growth	53.91%	US#280/3,112 Sec#55/269
Earnings Growth	-121.41%	US#2,127/3,112 Sec#69/269
Financial Health
Debt Ratio	184.59%	US#1,706/3,112 Sec#198/269
Total Debt	$523M	US#1,794/3,112 Sec#57/269
FCF	$-53M	US#2,474/3,112 Sec#116/269
Cash	$142M	US#1,971/3,112 Sec#150/269
Current Ratio	1.43x	US#1,748/3,112 Sec#247/269
Net Debt/EBITDA	7.41x	US#2,272/3,112 Sec#90/269
Performance
1Y Return	-23.22%	US#2,662/3,112 Sec#221/269
1M Return	-15.59%	US#2,837/3,112 Sec#207/269
From 52W High	-20.48%	US#1,754/3,112 Sec#111/269
1Y MDD	-63.33%	US#2,799/3,112 Sec#227/269
Trading
Volume	117,654 shares	US#2,886/3,112 Sec#261/269
Trading Value	$1M	US#3,007/3,112 Sec#254/269
Per Share
EPS	$0.07	US#2,036/3,112 Sec#73/269
BPS	$1.15	US#2,601/3,112 Sec#197/269